ANI Pledges To Keep Snapping Up Assets And Partnering

24 May 2019

• By Aidan Fry

US niche generics and brands player ANI Pharmaceuticals intends to keep using its cash flow to fund product acquisitions and partnerships, particularly in the injectables arena.

Basket — ANI Pharmaceuticals intends to keep shopping for baskets of ANDAs in the US • Source: Shutterstock

US-based specialty pharma player ANI Pharmaceuticals plans to continue with its strategy of building out both its pipeline and its marketing portfolio through acquisitions and alliances, rather than developing drugs on its own.

“We have substantial firepower to pursue strategic opportunities and we intend to continue to use our cash and cash availability...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aurobindo Addresses Rumor Of $5bn Zentiva Buyout

20 Aug 2025

• By Dave Wallace

Rumours are circulating that Aurobindo could be set to take ownership of Zentiva from current owner Advent in a $5bn transaction, which would represent one of the largest off-patent sector deals in some time.

$160m War Chest Readied For Aquestive’s Oral Epinephrine Film Launch

18 Aug 2025

• By Dean Rudge

Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.

Intas Expands Its Plasma Business With A European Acquisition

14 Aug 2025

• By Urtė Fultinavičiūtė

Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

13 Aug 2025

• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

18 Aug 2025

• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.